Tissue plasminogen activator (tPA) treatment for COVID 19 associated respiratory failure: A case Series

Authors

  • Md Motiul Islam Consultant, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh
  • Muhammad Mazharul Hoque Clinical Staff, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh
  • Tarikul Hamid Associate Consultant, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh
  • Muhammad Rabiul Halim Associate Consultant, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh
  • Kazi Nuruddin Ahmed Associate Consultant, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh
  • Rajib Hasan Specialist, Critical Care Medicine, Asgar Ali Hospital, Dhaka-1204, Bangladesh

DOI:

https://doi.org/10.3329/bccj.v10i1.59207

Keywords:

COVID-19, acute respiratory distress syndrome (ARDS), Thrombolysis, Coagulopathy, Tissue plasminogen activator (tPA).

Abstract

The global pandemic of COVID-19 has oversaturated the medical care facilities with a large proportion of patient associated with acute respiratory distress syndrome (ARDS). ARDS in patients with COVID-19 is associated with high incidence of pulmonary embolism, pulmonary hypertension and microthrombotic complications. Although heparin is frequently used to treat thrombotic pathology COVID-19, pulmonary embolism is still observed in severe cases. Pathology reports consistently demonstrate diffuse pulmonary microthrombi on autopsy, consistent with vascular occlusive etiology of respiratory failure rather than the more classic finding in ARDS. Pulmonary microthrombi induced respiratory failure is very difficult to prove because the patients are so critically ill that transfer to CT suit to do CT pulmonary angiogram (CTPA) often become unsafe for the patients. Moreover, performing V/Q scan is increasingly difficult in these settings. Here we report a case series of 10 patients with severe COVID-19 associated respiratory failure who were treated with tissue plasminogen activator (tPA).

Bangladesh Crit Care J March 2022; 10 (1): 62-67

Downloads

Download data is not yet available.
Abstract
35
PDF
43

Downloads

Published

2022-04-25

How to Cite

Islam, M. M. ., Hoque, M. M. ., Hamid, T. ., Halim, M. R. ., Ahmed, K. N., & Hasan, R. . (2022). Tissue plasminogen activator (tPA) treatment for COVID 19 associated respiratory failure: A case Series. Bangladesh Critical Care Journal, 10(1), 62–67. https://doi.org/10.3329/bccj.v10i1.59207

Issue

Vol. 10 No. 1 (2022)

Section

Case Reports

License

Upon acceptance for publication the copyright of the paper automatically transfers to the BCCJ and will not be published elsewhere either in part or whole without written permission of the copyright holder.

Except for personal use, no part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, photocopying, recording or otherwise without the prior written permission of the publisher.